Skip to content

Brain Activity and Oxygenation Inflammatory Bowel Disease (IBD) Patients

IBD | Maladaptive Behavior Associated With Physical Illness

Symptoms such as fatigue, sleep disturbances, anxiety and depression are common in patients with IBD, but the cause is unknown. Understanding how these behaviors occur in IBD and their role in symptoms may help improve management of IBD. How IBD leads to changes in brain function remains unclear. Inflammation and dysfunction of blood flow may occur in patients with IBD, which may be linked to these symptoms. Patients with IBD also have an alteration or imbalance of gut bacteria which may play a role in the development of the disease, but the exact mechanism remains poorly understood;as a result, there are limited therapeutic options available clinically to address this issue. An approved therapy, anti-TNF α, may be useful in improving brain and gut activity as well as quality of life. The purpose of this research study is to better understand brain and gut activity in the context of IBD to possibly improve treatments for the disease. In patients taking anti-TNFα therapy as prescribed clinically as standard of care, the investigators will measure brain activity using NIRS; gut microbiome using stool analysis and quality of life using various questionnaires.

null

Conditions de participation

  • Sexe:

    ALL

  • Âges admissibles:

    18 to 85

Critères de participation

Inclusion Criteria:

Eligible patients will be:

* \> 18 years of age with moderate-to-severe UC or (partial Mayo score \[excluding endoscopy\] ≥5 with rectal bleeding subscore ≥1; or total Mayo subscore 6-12 with RBS ≥1) or CD (Harvey-Bradshaw index \[HBI\] of 7 or greater, and active CD confirmed on POC bowel ultrasound (defined by bowel wall thickness \>3mm and positive Color doppler signal and a fecal calprotectin \> 50 μg/g ).
* based on their active disease status patients cannot be taking \> 20 mg prednisone daily and
* must be eligible for anti-TNF therapy as per standard of care (clinical decision made by IBD specialist caring for the patient).

Exclusion Criteria:

* patients with severely active UC (clinical signs of fulminant colitis or toxic megacolon) or CD (HBI \> 16), requiring \> 20 mg of prednisone daily at induction, suicidal ideation or psychosis.

Lieu de l'étude

University of Calgary
University of Calgary
Calgary, Alberta
Canada

Contactez l'équipe d'étude

Primary Contact

Blessing Odia

403-220-5782
Étude parrainée par
University of Calgary
Participants recherchés
Plus d'informations
ID de l'étude: NCT04733456